Archives
-
CDK4/6 and BET Inhibitors in Wnt-Driven PDAC
2026-10-01
Gu et al. show that CDK4/6 blockade can restrain pancreatic ductal adenocarcinoma proliferation while unintentionally enhancing migration, invasion, and epithelial-to-mesenchymal transition. Their study identifies GSK3β-mediated Wnt/β-catenin activation as a mechanistic liability and demonstrates that BET inhibition with JQ1 can restore antitumor activity in combination with palbociclib.
-
N3-kethoxal: From Guanine Chemistry to KAS-ATAC
2026-10-01
N3-kethoxal connects selective guanine labeling with bioorthogonal click chemistry and genome-scale assay design. This article explains how its chemistry supports RNA structure analysis, accessible-DNA mapping, and the distinctive KAS-ATAC measurement strategy.
-
Letrozole: Designing Causal Endocrine Assays
2026-09-30
Letrozole is a non-steroidal aromatase inhibitor that can reveal how estrogen synthesis connects to receptor, endocrine, and neural phenotypes. This guide presents a causal framework for choosing controls, interpreting readouts, and avoiding overstatement in breast cancer research.
-
Cy3 Goat Anti-Mouse IgG (H+L) Antibody Guide
2026-09-30
Cy3 Goat Anti-Mouse IgG (H+L) Antibody provides fluorescent detection of mouse primary antibodies in immunofluorescence, flow cytometry, and western blot workflows. It is intended for research assay development and optimization, not diagnostic, clinical, or medical use.
-
LGK-974 and the Next Logic of Wnt Translation
2026-09-29
LGK-974 provides a mechanistically precise way to test whether tumor cells depend on secreted Wnt ligands, while recent pancreatic cancer research highlights how Wnt pathway activity intersects with cell-cycle control, BET signaling, and epithelial-to-mesenchymal transition.
-
HIV-1 Nuclear Pore Remodeling in Resting T Cells
2026-09-29
The reference study identifies nuclear import at the nuclear pore complex as a major barrier to HIV-1 infection of resting CD4+ T cells and shows how cell–cell spread overcomes it. Its central advance is linking Env–CD4–LCK signalling during virological synapse formation to CDK1-dependent nucleoporin phosphorylation, without requiring cell-cycle entry.
-
Porcupine Inhibition for Sclerosteosis
2026-09-28
The 2025 Bone Research study tests LGK974-mediated PORCN inhibition as a pharmacological strategy for SOST-deficient high-bone-mass disease. In osteoblast cultures and Sost-deficient mice, treatment reduced Wnt-associated osteogenic activity and selected skeletal overgrowth phenotypes, while also revealing sex-dependent differences in target engagement.
-
Imatinib hydrochloride: Cancer Research Workflows
2026-09-28
Build reproducible CML and GIST experiments around imatinib’s reported v-Abl, c-Kit, and PDGFR activity—while separating target inhibition from downstream pathway effects. Practical dose, timing, and control strategies also help prevent a common overinterpretation: the p38α phosphatase findings in a recent preprint do not establish a dual-action effect for imatinib.
-
Viral RIPK3 Degradation Shapes Inflammation
2026-09-27
Liu et al. identify an orthopoxvirus protein family that recruits host SCF machinery to ubiquitinate and degrade RIPK3, thereby suppressing necroptosis. Viral-genetic and mouse experiments connect this mechanism to viral replication, inflammation, and disease severity, revealing a distinct strategy of immune evasion.
-
VX-702: Reading p38α Inhibition Beyond Cytokines
2026-09-26
VX-702 is a potent p38α MAPK inhibitor for investigating inflammatory signaling, but kinase activity and activation-loop phosphorylation are not interchangeable readouts. This article connects emerging phosphatase biology to practical assay choices while distinguishing established VX-702 data from mechanisms that still require direct testing.
-
BIBR 1532: Reading Telomerase and Telomere Signals
2026-09-25
BIBR 1532 is a selective telomerase inhibitor for studying hTERT, telomere maintenance, and cancer-cell responses. This article explains how to distinguish telomerase suppression from telomere attrition and DNA-damage-driven effects, using recent CF10–EdU findings to sharpen assay interpretation.
-
Cardamomin Protects Against Oxidative Stroke Injury
2026-09-25
A study of cardamomin from Amomum villosum Lour. links protection against oxidative damage in BV-2 cells and cerebral ischemic injury in rats to NRF2 signaling and AIFM1-associated cell-death pathways. Its combination of cellular assays, mechanistic analyses, and TTC-based tissue assessment provides a useful framework for evaluating candidate neuroprotective compounds, while leaving important questions about dosing, timing, and translation to human stroke unresolved.
-
ASB3 Targets MAVS to Suppress Antiviral Immunity
2026-09-24
The 2024 study identifies the E3 ligase ASB3 as a negative regulator of antiviral signaling: it promotes K48-linked ubiquitination and proteasomal degradation of MAVS at K297, weakening downstream TBK1–IRF3 activation. ASB3 loss strengthened antiviral responses in cellular models and reduced susceptibility to influenza infection in mice, pointing to a host regulatory mechanism whose relevance will need testing across additional viruses and models.
-
Belinostat (PXD101): Read Beyond Viability
2026-09-24
Belinostat (PXD101) offers a useful model for studying how histone deacetylase inhibition changes cancer-cell growth. This article shows why separating growth arrest from cell death can make preclinical response data more informative.
-
Ordered DNA Frameworks Improve Enzymatic Oligo Synthesis
2026-09-23
Li and colleagues report that presenting primers on a tetrahedral DNA nanostructure improves enzyme access during enzymatic oligonucleotide synthesis. The framework reduced deletion errors across patterned sequences and supported a 60-nucleotide DNA information-storage construct with a reported stepwise yield of 96.82%.